SCHEMBL18220163

SCHEMBL18220163

COCCNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N(C)C)ccc3c2)s1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
APP P05067 4/20 0.35
LMNA P02545 4/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
MITF O75030 1/20 0.32
MAPK1 P28482 1/20 0.32
MDM2 Q00987 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GAA P10253 1/20 0.30
HSD17B1 P14061 1/20 0.30
HSD17B2 P37059 1/20 0.30
ESRRA P11474 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19294129 0.91 MAPT (0.37) MAPTAPPALDH1A1MEN1KMT2A
SCHEMBL18220159 0.91 MAPT (0.37) MAPTAPPLMNAALDH1A1HPGD
SCHEMBL18220158 0.90 MAPT (0.36) MAPTAPPLMNAALDH1A1HPGD
SCHEMBL18220160 0.84 LMNA (0.49) MAPTAPPLMNAALDH1A1HPGD
SCHEMBL19294125 0.83 MAPT (0.36) MAPTAPPLMNAALDH1A1MEN1
SCHEMBL18221503 0.83 MAPT (0.34) MAPTAPP
SCHEMBL18220269 0.83 MAPT (0.36) MAPTAPP
SCHEMBL18220161 0.83 APP (0.47) MAPTAPPLMNAALDH1A1HPGD
SCHEMBL18220153 0.82 APP (0.47) MAPTAPPALDH1A1MEN1KMT2A
SCHEMBL19294126 0.82 MAPT (0.35) MAPTAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885LMNA 1263/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885LMNA 1263/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885LMNA 1263/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA MAPT 26/4885APP 1/4885LMNA 1283/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885LMNA 1263/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA MAPT 26/4885APP 1/4885LMNA 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.